Market capitalization | $203.65m |
Enterprise Value | $58.10m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 42.41 |
P/S ratio (TTM) P/S ratio | 148.65 |
P/B ratio (TTM) P/B ratio | 0.88 |
Sales growth (TTM) Sales growth | -76.63% |
Turnover (TTM) Turnover | $1.37m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
5 Analysts have issued a Century Therapeutics Inc forecast:
5 Analysts have issued a Century Therapeutics Inc forecast:
Mar '24 |
+/-
%
|
||
Net profit | -28 -28 |
10%
10%
|
|
Depreciation and amortization | 3.23 3.23 |
49%
49%
|
|
Share compensation | 3.21 3.21 |
16%
16%
|
|
Operating cash flow | -30 -30 |
9%
9%
|
|
Investments | 0.54 0.54 |
89%
89%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -31 -31 |
20%
20%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Brent Pfeiffenberger |
Employees | 165 |
Founded | 2018 |
Website | www.centurytx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.